Myopic choroidal neovascularisation (myopic CNV)

Myopic choroidal neovascularisation (myopic CNV) is one of the most feared complications of myopia, characterised by abnormal blood vessels that grow under the macula and affect the centre of the vision. While myopic CNV is historically thought to only occur in eyes with pathological myopia, it is now recognised that myopic CNV can occur at any degree of myopia and in eyes without typical myopic degenerative fundus changes.

Showing all 3 results

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
1
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price from
PIGF
,
VEGF-A
Fusion protein
Eylea®
40 mg/mL
0,8 mg
-80°C
2021.11
627,00 
view product
Max: 1
Min: 1
Step: 1
PIGF
,
VEGF-A
Fusion protein
Eylea®
40 mg/mL
0,8 mg
-80°C
2025.02
1.296,00 
view product
Max: 3
Min: 1
Step: 1
VEGF
Biosimilar
,
Monoclonal Antibody
Ximluci®
10 mg/mL
0,21 mg
tba
tba
680,00 
view product
Max: 10
Min: 5
Step: 1

Not looking for Myopic choroidal neovascularisation (myopic CNV)?

Search our therapeutic molecules product database